ÂÜÀòÂÒÂ×

Emmanuel Akporiaye is the Founder and CEO of Veana Therapeutics Inc, established in 2012 as a spin-off from the Providence Cancer Institute, focused on developing safer and effective oral therapies for cancer patients. In addition to leadership at Veana, Emmanuel serves as an Adjunct Scientist at Legacy Health and an Adjunct Member at Earle A. Chiles Research Institute, alongside previous roles as Collaborator at the same institute. Emmanuel has significant experience in academic settings, having held positions such as Professor and Interim Department Chair at the University of Arizona, where a focus on tumor cell-immune cell interactions in cancer immunology research was established. Previous experience includes serving as Chief of Scientific Career Development and Division Chief of Experimental Biology at Sidra Medical and Research Center. Emmanuel's education includes a PhD in Microbiology from The University of New Mexico and post-doctoral training in Cancer Immunology at Los Alamos National Laboratory.